Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VizionfocusTPE:4771 -0.49%91 EBITDA Margin % is 43.81% as of Dec. 2025, which is 25% above its 10-year median of 35.02. GuruFocus rates TPE:4771 with a GF Score™ of 91/100 and a GF Value™ of NT$294.76 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Vizionfocus ranks better than 96.94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vizionfocus's EBITDA for the
three
months ended in Dec. 2025 was NT$417 Mil. Vizionfocus's Revenue for the
three
months ended in Dec. 2025 was NT$951 Mil. Therefore, Vizionfocus's EBITDA margin for the quarter that ended in Dec. 2025 was 43.81%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vizionfocus EBITDA Margin % Related Terms
Vizionfocus EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vizionfocus's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4771 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Vizionfocus's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vizionfocus EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vizionfocus's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vizionfocus's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vizionfocus (TPE:4771) has a EBITDA Margin % of 43.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vizionfocus and its competitors. This is 25% above median its historical median of 35.02. Over the past decade, Vizionfocus' EBITDA Margin % has ranged from 9.90 to 44.06. According to the industry distribution chart, Vizionfocus ranks #25 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 3.1%.
Is Vizionfocus' EBITDA Margin % too high?
Vizionfocus' current EBITDA Margin % of 43.81% is 25% above median its 10-year median of 35.02. Over the past 10 years, this metric has ranged from a low of 9.90 to a high of 44.06. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Vizionfocus' value of 43.81% is 487.7% above this industry median. Based on the distribution chart, Vizionfocus ranks #25 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vizionfocus has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vizionfocus' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Vizionfocus ranks #25 out of 816 companies for EBITDA Margin %. This places Vizionfocus in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.46. Vizionfocus' value of 43.81% is 487.7% above this benchmark. Historically, Vizionfocus' own EBITDA Margin % has ranged from 9.90 to 44.06 over the past decade. While the company's 10-year median is 35.02 vs. the industry median of 7.46, Vizionfocus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vizionfocus's current EBITDA Margin % of 43.81% is 487.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vizionfocus and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vizionfocus's current EBITDA Margin % is 43.81%, which is 25% above median its own 10-year median of 35.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vizionfocus stock overvalued right now?
Based on GuruFocus' analysis, Vizionfocus (TPE:4771) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$294.76, compared to a current price of NT$203.00 — trading 31.1% below its estimated fair value. The current EBITDA Margin % is 43.81%, which is 25% above median its 10-year median of 35.02 and 487.7% above the Medical Devices & Instruments industry median of 7.46. Vizionfocus' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vizionfocus (TPE:4771), the current EBITDA Margin % is 43.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vizionfocus (TPE:4771) Overvalued in 2026?
Based on GuruFocus' analysis, Vizionfocus stock appears to be undervalued.
The current stock price of NT$203.00 is trading 31.1% below its estimated GF Value™ of NT$294.76.
GuruFocus considers Vizionfocus to be Significantly Undervalued.
Key valuation signals for TPE:4771:
EBITDA Margin %: 43.81% (25% above median its 10-year median of 35.02)
GF Value™: NT$294.76 vs. price of NT$203.00 (31.1% below fair value)
Industry Position: 487.7% above the Medical Devices & Instruments median (#25 of 816)
No single metric tells the full story. See the TPE:4771 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vizionfocus Inc is mainly engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments, international trading, and other consulting services. The Company operates through the VIZIONFOCUS segment, which generates maximum revenue and is engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments, international trading, and other consulting services, and the Jiangsu Vizionfocus Inc. segment, whose main business includes the research and development, design, and production of contact lenses, as well as the wholesale, import, and export of related products.
91GF Score
Get the complete analysis for TPE:4771
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4771 has been successfully added to your 
